Leukemia-Lymphoma 2023

Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing.

The Food and Drug Administration, in a flurry of activity, approved three new medications across a three-month period earlier this year.

MRD testing began among patients with chronic myeloid leukemia, a disease that lends itself to gauging MRD because it is driven by a specific genetic mutation.

Why minimal residual disease testing is the "gold standard" for some patients and providers.